*Purpose: Liver transplant (LT) recipients are at a higher risk of de novo malignancies. In this study we aim to study the distribution and incidence of de novo hematological malignancies after liver transplantation in different parts of the world.

*Methods: A systematic search of Medline and Embase was conducted; studies utilizing transplant registries and reporting standardized incidence ratios (SIR) of de novo malignancies among LT patients were included. SIRs were pooled utilizing a random effects model and reported with their 95% confidence intervals (CI).

*Results: Overall, 11 studies utilizing data from 9 national registries were identified. The pooled global SIR for all de novo cancers post-LT was 2.51 (2.25-5.77; figure 1), with the highest SIR reported in the Japanese population and the lowest SIR reported in the English and French population. The pooled global SIR for Non-Hodgkin’s Lymphoma (NHL) was 10.34 (7.57-13.11), with the highest SIR reported in the Canadian population, and the lowest SIR reported in the Norwegian population (figure 2a). The pooled global SIR for Hodgkin’s Lymphoma (HL) was 3.79 (2.56-5.01), with the highest SIR reported in the English population, and the lowest SIR reported in the Swedish population (figure 2b). The pooled global SIR of Multiple myeloma was 1.25 (0.09-2.41), with the highest reported SIR in the Nordic population, and the lowest SIR reported in the English population (figure 2c). The pooled global SIR for Leukemia was 1.91 (0.66-3.16), with the highest SIR reported in the Japanese population, and the lowest SIR reported in the Nordic population (figure 2d).

*Conclusions: LT recipients are at a higher risk of developing NHL, HL, leukemias and multiple myeloma, compared to the general population. There are significant regional variations in the SIR for hematological malignancies among the liver transplant recipients that warrant further investigation of risk factors.

« Back to 2020 American Transplant Congress